Dual-Targeted CAR-T (LV20.19) for Relapsed/Refractory #CLL: Clinical Trial Results | EHA 2026

Dr. Nirav Shah from Medical College of Wisconsin presents breakthrough clinical trial data on a dual-targeted CAR-T cell therapy (LV20.19) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Presented at the European Hematology Association (EHA) 2026 meeting in Stockholm.

KEY HIGHLIGHTS:
- Current CAR-T limitation: Existing approved therapies target only CD19
- New approach: LV20.19 targets both CD19 and CD20
- Phase 1 Trial Results (19 patients):
  - Overall response rate: 90%
  - Complete remission rate: 79%
  - 2-year progression-free survival: 77%
  - Average prior therapies: 4 lines

SAFETY PROFILE:
- Manageable cytokine release syndrome
- Secondary inflammatory syndrome (HLH-type presentation) in ~50% of patients
- Both safety concerns being effectively managed

This dual-targeted approach shows promise for improving outcomes in heavily pre-treated CLL patients who have exhausted standard options.

Learn more: https://linktr.ee/HealthTreeUniversity

TIMESTAMPS:
0:00 Introduction & Context
0:10 What is CLL and CAR-T Therapy?
0:25 Current Approved CAR-T: CD19-Only Targeting
1:04 Limitations & Need for Better Options
1:14 Dual-Targeted CAR-T Approach: CD19 + CD20
1:45 Phase 1 Trial Design & Patient Details
2:24 Efficacy Results: Response Rates & Remission
2:48 2-Year Progression-Free Survival Data
3:00 Safety Profile & Toxicity Management
3:22 Conclusion & Future Opportunities

#CLL #CAR-T #Lymphoma #ClinicalTrial #EHA2026